Oral Abstracts • OFID 2017:4 (Suppl 1) • S23 treated × 6 months) were included. Whole blood VL was determined by real-time PCR at a central laboratory before therapy (baseline, BL) and periodically for 6 months.
Background.
A recently completed Phase 3 randomized, controlled, double-blind, multicenter study of infants with symptomatic congenital cytomegalovirus (CMV) disease receiving 6 months of oral valganciclovir (VGCV) therapy represents the largest such population in which to evaluate treatment-emergent antiviral resistance. The most common mechanism of CMV antiviral resistance occurs through mutations in the CMV UL97 gene that confer resistance to ganciclovir (GCV). Genotypic resistance analyses were performed on infants receiving 6 months of VGCV to assess the incidence of antiviral resistance due to UL97 sequence variants.
Methods. Resistance analyses were performed by conventional DNA sequencing of the UL97 gene at multiple time points. Following CMV DNA extraction from frozen whole blood specimens, the UL97 gene was amplified with a double nested polymerase chain reaction method and sequenced to identify polymorphisms and mutations that might confer GCV resistance.
Results. Forty-six infants with symptomatic CMV disease who received a 6-month course of VGCV underwent resistance analysis to identify UL97 sequence variants. In addition to a range of natural polymorphisms known to have no effect on antiviral susceptibility, 2 subjects developed UL97 mutations known to confer resistance to GCV (A594V and G598S detected in one subject; E596G detected in another), yielding an incidence of 4%. Each of these resistance mutations occurred in specimens collected after at least 4 months of antiviral therapy. As evaluated in the original Phase 3 trial, neither of these infants showed an improvement in hearing outcome.
Conclusion. The development of treatment-emergent UL97 resistance mutations was determined in a controlled study population of infants with congenital CMV disease receiving 6 months of VGCV. This targeted resistance analysis demonstrated an incidence approaching the total incidence of antiviral resistance for CMV disease in some immunocompromised populations, such as solid-organ transplant recipients. Further studies within this study population are warranted to elucidate the risk of emerging antiviral resistance and to assess clinical impact as well as the potential need for combination antiviral therapy.
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Programmatic Congenital CMV Universal Screening Program
Maria Carrillo-Marquez, MD Background. CMV is the most common congenital infection (cCMV). Traditional identification strategies including hearing screen and physical exam are insensitive and miss affected infants. To improve identification of infected newborns, we established a universal, institutional cCMV newborn screening program.
Methods. All newborns born or transferred to nurseries in a hospital system in Memphis, Tennessee between March 2016 and April 2017 were screened for cCMV. Infant saliva was collected on a Copan swab prior to discharge and within 2 weeks of birth. Specimens were centrally processed using a real-time CMV PCR assay (Simplexa™ CMV) (DiaSorin, Cypress CA) amplifying the UL83 gene, and the 3M Integrated Cycler. Parents received educational materials on cCMV testing and natural history prior to specimen collection. All patients with a positive screen had a full evaluation including physical exam, eye exam, hearing testing, CBC, chemistries and head ultrasound (HUS).
Results. There were 35/6,114 (0.6%) positive screens. Of 35, 16 (45.7%) were male and 5 (14%) were less than 37 weeks gestation. Thirty-one of 35 saliva specimens were collected on day 0 or 1 of life. All patients were evaluated by an infectious disease specialist at a median of 15 days of age. Confirmatory urine PCR was positive in 25/33 (76%) tested. Overall, 11/25 (44%) with confirmed congenital CMV were symptomatic. This included 28% with microcephaly and 20% with low birth weight. Six (24%) failed newborn hearing screening of one or both ears. Other abnormalities included thrombocytopenia (5%), elevated ALT (10%), elevated direct bilirubin (5%), and abnormal HUS (11/25, 44%), of which 7/11 had lenticulostriate vasculopathy and 2/11 had intracranial calcifications. Twelve infected infants had an eye examination and none had retinitis. Eleven infants were offered therapy and five were treated. Ten of 25 congenitally infected infants had audiology follow-up by 6 months with four abnormal. All infants were referred for early intervention.
Conclusion.
We have demonstrated the feasibility of implementing large-scale, saliva-based cCMV screening program within one hospital system. Universal screening detected twice as many infected infants than would have targeted screening based on newborn hearing screen and growth parameters. Methods. Beginning in 2015, we used a One Health approach and serial sampling to prospectively study 299 swine workers and 100 controls, their 9000 pigs, and six pig farm environments in China for influenza A viruses (IAVs) using molecular, culture, and immunological techniques. Study subjects were closely monitored for influenza-like illness (ILI) events.
Results. Upon enrollment, swine workers had higher serum neutralizing antibody titers against swine H1N1 and higher nasal wash total IgA and specific IgA titers against swine H1N1 and H3N2 viruses. Over a period of 12 months, IAVs were detected by qRT-PCR in 52 (12%) of 432 environmental swabs, 275 (7.6%) of 3600 pig oral secretion, 25 (5.8%) of 432 water, 24 (5.5%) of 432 aerosol, and 20 (4.6%) of 432 fecal-slurry specimens. Five (15.6%) of 32 subjects with ILI events had nasopharyngeal swab specimens that were positive for IAV and 17 (53%) demonstrated 4-fold rises in neutralization titers against a swine virus. Reassorted Eurasian avian-like swine H1N1, pdm09(H1N1)-like virus, and swine-like H3N2 viruses were identified in pig farms. The H1N1 viruses were nearly genetically identical with the human H1N1 viruses isolated from the subjects with ILI.
Conclusion. There was considerable evidence of A(H1N1)pdm09-like, swine H1N1 and swine H3N2 viruses reassorting and circulating within the pig farms and crossing species. These data suggest that stronger surveillance for novel influenza virus emergence within swine farms is imperative.
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